comparemela.com

Latest Breaking News On - Hepatocellular carcinoma - Page 5 : comparemela.com

IMBrave-050 Study Overview

Dr Shroff breaks down the combination of atezolizumab and bevacizumab as outlined by the IMBrave-050 study.

Evolving-treatments
Hepatocellular-carcinoma
Second-line-therapy-for-hcc
Tki-vs-io-in-hcc
Regorafenib-post-atezo-bev
Cabozantinib-in-hcc
Celestial-study
Child-pughb-patients
Liver-directed-therapy
Advanced-hcc-therapies
Additional-data-on-hcc

EMERALD-1 Study: Outshining Negative Clinical Trials Based Upon TKI- and Liver-directed Therapies

Drs Gong and Covey emphasize the impact of TACE + durvalumab ± bevacizumab combination therapy surrounding HCC treatment strategy.

Evolving-treatments
Hepatocellular-carcinoma
Outshining-negative-clinical-trials-based-upon
Tkis-in-hcc
Durvalumab-tace-bev
Frontline-systemic-therapy
Durva-treme-regimen
Immunotherapy-for-hcc
Imbrave150-study
Atezolizumab-plus-bevacizumab

Research team uses AI to predict risk of liver cancer

Research team uses AI to predict risk of liver cancer
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United-states
Americans
Frederick-meyers
Souvik-sarkar
Aniket-alurwar
Data-sciences
Uc-davis-center
Uc-davis-health
Gastro-hep-advances
Precision-medicine
Internal-medicine
Gradient-boosted-trees

Real-time navigation is a useful tool for liver cancer procedures, according to new study

Real-time navigation is a useful tool for liver cancer procedures, according to new study
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United-states
America
Yoshiko-iwai
Davida-gerber
Christianr-holmes
Uc-college-of-medicine
A-university-of-cincinnati-cancer-center
Department-of-surgery
Cincinnati-cancer-center
North-america
Integrating-navigation-assisted-ablation
Locoregional-treatment

TACE Plus Durvalumab and Bevacizumab Could Alter SOC in Embolization-Eligible, Unresectable HCC

Riccardo Lencioni, MD, discusses how TACE, durvalumab, and bevacizumab, could represent a new standard of care in embolization-eligible HCC.

Italy
Riccardo-lencioni
Department-of-surgery
Cancers-symposium
Critical-area-pathology
Riccardo-lencioni
D
Chemoembolization-tace-
Urvalumab-imfinzi-
Nd-bevacizumab-avastin-
Hepatocellular-carcinoma
Hcc

vimarsana © 2020. All Rights Reserved.